yttrium Y 90-ibritumomab tiuxetan

{
  "id": "MLC-T-ONC-009453",
  "term": "yttrium Y 90-ibritumomab tiuxetan",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with the drug rituximab to treat certain types of B-cell non-Hodgkin lymphoma. It is also being studied in the treatment of other types of B-cell tumors. Yttrium Y 90-ibritumomab tiuxetan contains a monoclonal antibody that binds to a protein called CD20, which is found on B cells. It also contains a radioactive substance called yttrium Y 90, which may help kill cancer cells. Yttrium Y 90-ibritumomab tiuxetan is a type of radioimmunoconjugate. Also called 90Y-ibritumomab tiuxetan, 90Y-Zevalin, and IDEC-Y2B8.",
    "A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90). Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation."
  ],
  "synonyms": [
    "90Y-ibritumomab tiuxetan",
    "90Y-Zevalin",
    "IDEC-Y2B8",
    "Y90 Zevalin",
    "90Y ibritumomab tiuxetan",
    "IDEC-Y2B8 monoclonal antibody"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/yttrium-y-90-ibritumomab-tiuxetan/"
}